scholarly journals Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

2009 ◽  
Vol 11 (S3) ◽  
Author(s):  
Stephen RD Johnston
Keyword(s):  
Drug Development ◽  
Full Potential ◽  
New Agents ◽  
Current Drug

scholarly journals Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs

2019 ◽  
Author(s):  
Daniele Parisi ◽  
Melissa F. Adasme ◽  
Anastasia Sveshnikova ◽  
Yves Moreau ◽  
Michael Schroeder
Keyword(s):  
Drug Development ◽  
Drug Target ◽  
Drug Repositioning ◽  
Close Relation ◽  
Full Potential ◽  
Development Cost ◽  
Computational Power ◽  
Future Developments ◽  
Current Drug ◽  
Repurposed Drugs

ABSTRACTDrug repositioning aims to find new indications for existing drugs, in order to reduce drug development cost and time. Currently, numerous successful stories of drug repositioning have been reported and many drugs are already available on the market. Although many of those cases are products of serendipitous findings, repositioning opportunities can be uncovered systematically by following either a disease-centric approach, as a result of a close relation between an old and new indication, a target-centric one, which links a known target and its established drug to a new indication, or a drug-centric approach, which connects a known drug to a new target and its associated indication. The three approaches differ in their complexity, potential, and limits, and most important the necessary starting information and computational power. Which one is predominant in current drug repositioning and what does this imply for future developments? To address these questions, we systematically evaluated over 100 drugs, 200 targets structures and over 300 indications from the Drug Repositioning Database. Each of the analysed cases has been classified based on one of the three repositioning approaches, showing that the majority, more than 60%, falls within the disease-centric definition, around 30% within the target-centric, and only less than 10% within the drug-centric. We therefore concluded that so far repositioning has mainly been disease and target repositioning and not, as drug repositioning, as expected by definition. We discuss the reasons and suggest directions to exploit the full potential of techniques useful for drug-centric in order to sustain future rationale repositioning pipelines.

Weaknesses in the System of Promoting and Marketing Drugs

1974 ◽  
Vol 4 (3) ◽  
pp. 260-263
Author(s):  
James Turner
Keyword(s):  
Public Sector ◽  
Pharmaceutical Industry ◽  
Drug Development ◽  
Economic Structure ◽  
Drug Industry ◽  
Specific Drug ◽  
The Public ◽  
Current Drug ◽  
Consumer Organizations ◽  
The Impact

Although critical of several specific drug industry practices as being major contributions to the current over-medicated society controversy, Mr. Turner believes that the pharmaceutical industry can work together with consumer organizations and the public sector in resolving these issues. Of particular interest is his observation that the economic structure of current drug development and research prevents the manufacturer from assessing the impact of a drug in terms of necessary health benefits.

Current drug development portfolio for antimalarial therapies

2005 ◽  
Vol 5 (5) ◽  
pp. 473-478 ◽  
Author(s):  
G BIAGINI ◽  
P ONEILL ◽  
P BRAY ◽  
S WARD
Keyword(s):  
Drug Development ◽  
Current Drug
Sign in / Sign up

Export Citation Format

Share Document